| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
An ingenious design for peptide vaccines
|
Yano, Akira
|
|
2005
|
23 |
17-18 |
p. 2322-2326
5 p.
|
article
|
| 2 |
Antigenic complementarity between HIV and other AIDS-associated infections results in idiotype–antiidiotype antibody complexes that cross react with lymphocyte proteins
|
Root-Bernstein, Robert
|
|
2005
|
23 |
17-18 |
p. 2160-2163
4 p.
|
article
|
| 3 |
Antigenome technology: a novel approach for the selection of bacterial vaccine candidate antigens
|
Meinke, Andreas
|
|
2005
|
23 |
17-18 |
p. 2035-2041
7 p.
|
article
|
| 4 |
Assessment of immunological competence and SV40 specific recall immunity in malignant pleural mesothelioma
|
Jasani, Bharat
|
|
2005
|
23 |
17-18 |
p. 2399-2402
4 p.
|
article
|
| 5 |
A Strategic Vaccine Facility for the UK
|
Duggan, Jacqueline M.
|
|
2005
|
23 |
17-18 |
p. 2090-2094
5 p.
|
article
|
| 6 |
Bacterial otitis media: a vaccine preventable disease?
|
Cripps, Allan W.
|
|
2005
|
23 |
17-18 |
p. 2304-2310
7 p.
|
article
|
| 7 |
Cancer vaccines and immunotherapies: emerging perspectives
|
Henderson, Robert A.
|
|
2005
|
23 |
17-18 |
p. 2359-2362
4 p.
|
article
|
| 8 |
Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain)
|
Navas, E.
|
|
2005
|
23 |
17-18 |
p. 2342-2348
7 p.
|
article
|
| 9 |
Current progress in tuberculosis vaccine development
|
Orme, Ian M.
|
|
2005
|
23 |
17-18 |
p. 2105-2108
4 p.
|
article
|
| 10 |
DermaVir, a novel HIV immunisation technology
|
Lori, Franco
|
|
2005
|
23 |
17-18 |
p. 2030-2034
5 p.
|
article
|
| 11 |
Developing an epitope-driven tuberculosis (TB) vaccine
|
De Groot, Anne S.
|
|
2005
|
23 |
17-18 |
p. 2121-2131
11 p.
|
article
|
| 12 |
Development of a therapeutic vaccine for HSV-2
|
Hosken, Nancy A.
|
|
2005
|
23 |
17-18 |
p. 2395-2398
4 p.
|
article
|
| 13 |
Do successful tuberculosis vaccines need to be immunoregulatory rather than merely Th1-boosting?
|
Rook, Graham A.W.
|
|
2005
|
23 |
17-18 |
p. 2115-2120
6 p.
|
article
|
| 14 |
Dramatic decline in acute hepatitis B infection and disease incidence rates among adolescents and young people after 12 years of a mass hepatitis B vaccination programme of pre-adolescents in the schools of Catalonia (Spain)
|
Salleras, L.
|
|
2005
|
23 |
17-18 |
p. 2181-2184
4 p.
|
article
|
| 15 |
Editorial Board / Aims ; Scope
|
|
|
2005
|
23 |
17-18 |
p. IFC-
1 p.
|
article
|
| 16 |
Efficacy of DNA vaccination against western equine encephalitis virus infection
|
Nagata, Les P.
|
|
2005
|
23 |
17-18 |
p. 2280-2283
4 p.
|
article
|
| 17 |
Efficiency of the incorporation of the hepatitis A vaccine as a combined A+B vaccine to the hepatitis B vaccination programme of preadolescents in schools
|
Navas, E.
|
|
2005
|
23 |
17-18 |
p. 2185-2189
5 p.
|
article
|
| 18 |
Evaluating the post-licensure effectiveness of a group B meningococcal vaccine in New Zealand: a multi-faceted strategy
|
Ameratunga, Shanthi
|
|
2005
|
23 |
17-18 |
p. 2231-2234
4 p.
|
article
|
| 19 |
Evaluation of a synthetic vaccine construct as antigen for the detection of HIV-induced humoral responses
|
Hewer, R.
|
|
2005
|
23 |
17-18 |
p. 2164-2167
4 p.
|
article
|
| 20 |
Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets
|
Czub, Markus
|
|
2005
|
23 |
17-18 |
p. 2273-2279
7 p.
|
article
|
| 21 |
Experimental disease models for the assessment of meningococcal vaccines
|
Gorringe, A.R.
|
|
2005
|
23 |
17-18 |
p. 2214-2217
4 p.
|
article
|
| 22 |
Expression of the synthetic neutralizing epitope gene of porcine epidemic diarrhea virus in tobacco plants without nicotine
|
Kang, Tae-Jin
|
|
2005
|
23 |
17-18 |
p. 2294-2297
4 p.
|
article
|
| 23 |
From secondary prevention to primary prevention: a unique strategy that gives hope to a country ravaged by meningococcal disease
|
O’Hallahan, Jane
|
|
2005
|
23 |
17-18 |
p. 2197-2201
5 p.
|
article
|
| 24 |
Fusing subunit antigens to interleukin-2 and encapsulating them in liposomes improves their antigenicity but not their protective efficacy
|
Wales, J.R.
|
|
2005
|
23 |
17-18 |
p. 2339-2341
3 p.
|
article
|
| 25 |
General strategies for efficient adjuvant incorporation of recombinant subunit immunogens
|
Wikman, Maria
|
|
2005
|
23 |
17-18 |
p. 2331-2335
5 p.
|
article
|
| 26 |
Generation of anti-β-amyloid antibodies via phage display technology towards Alzheimer's disease vaccination
|
Solomon, Beka
|
|
2005
|
23 |
17-18 |
p. 2327-2330
4 p.
|
article
|
| 27 |
Health economic research on vaccinations and immunisation practices—an introductory primer
|
Szucs, Thomas D.
|
|
2005
|
23 |
17-18 |
p. 2095-2103
9 p.
|
article
|
| 28 |
HIV vaccine development by computer assisted design: the GAIA vaccine
|
De Groot, Anne S.
|
|
2005
|
23 |
17-18 |
p. 2136-2148
13 p.
|
article
|
| 29 |
Human-derived, plant-produced monoclonal antibody for the treatment of anthrax
|
Hull, Anna K.
|
|
2005
|
23 |
17-18 |
p. 2082-2086
5 p.
|
article
|
| 30 |
Immunopropylactic approaches against chemical carcinogenesis
|
De Buck, Stefan S.
|
|
2005
|
23 |
17-18 |
p. 2403-2406
4 p.
|
article
|
| 31 |
Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits
|
Uyl-de Groot, C.A.
|
|
2005
|
23 |
17-18 |
p. 2379-2387
9 p.
|
article
|
| 32 |
Induction of broadly neutralizing antibodies against measles virus mutants using a polyepitope vaccine strategy
|
Bouche, Fabienne B.
|
|
2005
|
23 |
17-18 |
p. 2074-2077
4 p.
|
article
|
| 33 |
Induction of immune responses and partial protection in mice after skin immunization with rotavirus VP6 protein and the adjuvant LT(R192G)
|
Choi, Anthony H.-C.
|
|
2005
|
23 |
17-18 |
p. 2290-2293
4 p.
|
article
|
| 34 |
Linkage of Ii-Key segment to gp100(46–58) epitope enhances the production of epitope-specific antibodies
|
Kallinteris, Nikoletta L.
|
|
2005
|
23 |
17-18 |
p. 2336-2338
3 p.
|
article
|
| 35 |
Magnifection—a new platform for expressing recombinant vaccines in plants
|
Gleba, Y.
|
|
2005
|
23 |
17-18 |
p. 2042-2048
7 p.
|
article
|
| 36 |
Malaria vaccines: using models of immunity and functional genomics tools to accelerate the development of vaccines against Plasmodium falciparum
|
Duffy, Patrick E.
|
|
2005
|
23 |
17-18 |
p. 2235-2242
8 p.
|
article
|
| 37 |
Meningococcal surrogates of protection—serum bactericidal antibody activity
|
Borrow, Ray
|
|
2005
|
23 |
17-18 |
p. 2222-2227
6 p.
|
article
|
| 38 |
MeNZB™: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain
|
Oster, Philipp
|
|
2005
|
23 |
17-18 |
p. 2191-2196
6 p.
|
article
|
| 39 |
New Zealand's epidemic of meningococcal disease described using molecular analysis: implications for vaccine delivery
|
Dyet, K.
|
|
2005
|
23 |
17-18 |
p. 2228-2230
3 p.
|
article
|
| 40 |
[No title]
|
Kurstak, Prof. Dr Edouard
|
|
2005
|
23 |
17-18 |
p. 2023-
1 p.
|
article
|
| 41 |
Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model
|
Kita, Yoko
|
|
2005
|
23 |
17-18 |
p. 2132-2135
4 p.
|
article
|
| 42 |
On the need for, and the delivery of, cross-protective vaccines
|
Spier, R.E.
|
|
2005
|
23 |
17-18 |
p. 2027-2029
3 p.
|
article
|
| 43 |
Outer membrane protein (OMP) based vaccine for Neisseria meningitidis serogroup B
|
Pillai, Subramonia
|
|
2005
|
23 |
17-18 |
p. 2206-2209
4 p.
|
article
|
| 44 |
Paediatric infections: prevention of transmission and disease—implications for adults
|
McIntosh, E. David
|
|
2005
|
23 |
17-18 |
p. 2087-2089
3 p.
|
article
|
| 45 |
Peptide-based candidate vaccine against respiratory syncytial virus
|
Yusibov, Vidadi
|
|
2005
|
23 |
17-18 |
p. 2261-2265
5 p.
|
article
|
| 46 |
Plasmid maintenance systems suitable for GMO-based bacterial vaccines
|
Spreng, Simone
|
|
2005
|
23 |
17-18 |
p. 2060-2065
6 p.
|
article
|
| 47 |
Plasmid vaccination of stable HIV-positive subjects on antiviral treatment results in enhanced CD8 T-cell immunity and increased control of viral “blips”
|
MacGregor, Rob Roy
|
|
2005
|
23 |
17-18 |
p. 2066-2073
8 p.
|
article
|
| 48 |
Policy evaluation for the subsidy for influenza vaccination in elderly
|
Ohkusa, Yasushi
|
|
2005
|
23 |
17-18 |
p. 2256-2260
5 p.
|
article
|
| 49 |
Prophylaxis of acute respiratory virus infections using nucleic acid-based drugs
|
Wong, Jonathan P.
|
|
2005
|
23 |
17-18 |
p. 2266-2268
3 p.
|
article
|
| 50 |
Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides
|
Olive, Colleen
|
|
2005
|
23 |
17-18 |
p. 2298-2303
6 p.
|
article
|
| 51 |
Protection by dendritic cells-based HIV synthetic peptide cocktail vaccine: preclinical studies in the SHIV-rhesus model
|
Nehete, Pramod N.
|
|
2005
|
23 |
17-18 |
p. 2154-2159
6 p.
|
article
|
| 52 |
Rabies control in South and Southeast Asia
|
Wilde, Henry
|
|
2005
|
23 |
17-18 |
p. 2284-2289
6 p.
|
article
|
| 53 |
Rapid progress in new vaccines development, immunisation and immunotherapy
|
Kurstak, Edouard
|
|
2005
|
23 |
17-18 |
p. 2024-2026
3 p.
|
article
|
| 54 |
Real world TB vaccines: clinical trials in TB-endemic regions
|
Doherty, T. Mark
|
|
2005
|
23 |
17-18 |
p. 2109-2114
6 p.
|
article
|
| 55 |
Requiring influenza vaccination for health care workers: seven truths we must accept
|
Poland, Gregory A.
|
|
2005
|
23 |
17-18 |
p. 2251-2255
5 p.
|
article
|
| 56 |
Sample sizes and negative studies in clinical vaccine research
|
Jacobson, Robert M.
|
|
2005
|
23 |
17-18 |
p. 2318-2321
4 p.
|
article
|
| 57 |
Site-specific peptide vaccines for immunotherapy and immunization against chronic diseases, cancer, infectious diseases, and for veterinary applications
|
Wang, Chang Yi
|
|
2005
|
23 |
17-18 |
p. 2049-2056
8 p.
|
article
|
| 58 |
Studies of equivalence in clinical vaccine research
|
Jacobson, Robert M.
|
|
2005
|
23 |
17-18 |
p. 2315-2317
3 p.
|
article
|
| 59 |
Surveillance system of vaccine adverse events and local data analysis – the experience in a middle-sized city in Brazil, 1999–2001
|
Fernandes, Guilherme Côrtes
|
|
2005
|
23 |
17-18 |
p. 2349-2353
5 p.
|
article
|
| 60 |
Targeting carbohydrate antigens in HIV vaccine development
|
Pashov, Anastas
|
|
2005
|
23 |
17-18 |
p. 2168-2175
8 p.
|
article
|
| 61 |
T-cell vaccination against anti-CD4 autoimmunity in HIV-1 subtypes B and C-infected patients—An extended open trial
|
Abulafia-Lapid, Rivka
|
|
2005
|
23 |
17-18 |
p. 2149-2153
5 p.
|
article
|
| 62 |
The concept of “tailor-made”, protein-based, outer membrane vesicle vaccines against meningococcal disease
|
Holst, Johan
|
|
2005
|
23 |
17-18 |
p. 2202-2205
4 p.
|
article
|
| 63 |
The development of a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles
|
Gorringe, Andrew
|
|
2005
|
23 |
17-18 |
p. 2210-2213
4 p.
|
article
|
| 64 |
The development of vaccines against SARS corona virus in mice and SCID-PBL/hu mice
|
Okada, Masaji
|
|
2005
|
23 |
17-18 |
p. 2269-2272
4 p.
|
article
|
| 65 |
The “Green Channel” of the Veneto region as a model for vaccine safety monitoring in Italy
|
Zanoni, G.
|
|
2005
|
23 |
17-18 |
p. 2354-2358
5 p.
|
article
|
| 66 |
Therapeutic vaccines: a solution to the prevention problem?
|
Dawson, Angus
|
|
2005
|
23 |
17-18 |
p. 2363-2366
4 p.
|
article
|
| 67 |
The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer
|
M., Adams
|
|
2005
|
23 |
17-18 |
p. 2374-2378
5 p.
|
article
|
| 68 |
The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program
|
Poland, Gregory A.
|
|
2005
|
23 |
17-18 |
p. 2078-2081
4 p.
|
article
|
| 69 |
Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research
|
Heppner Jr., D. Gray
|
|
2005
|
23 |
17-18 |
p. 2243-2250
8 p.
|
article
|
| 70 |
Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results
|
Trefzer, Uwe
|
|
2005
|
23 |
17-18 |
p. 2367-2373
7 p.
|
article
|
| 71 |
United States Pharmacopeia activities in the area of vaccines, virology and immunology
|
Morris, Tina S.
|
|
2005
|
23 |
17-18 |
p. 2311-2313
3 p.
|
article
|
| 72 |
Vaccination against hepatitis A during outbreaks starting in schools: what can we learn from experiences in central Italy?
|
Bonanni, Paolo
|
|
2005
|
23 |
17-18 |
p. 2176-2180
5 p.
|
article
|
| 73 |
Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control
|
Franco, Eduardo L.
|
|
2005
|
23 |
17-18 |
p. 2388-2394
7 p.
|
article
|
| 74 |
Vaccination markers: designing unique antigens to be added to vaccines to differentiate between natural infection and vaccination
|
Root-Bernstein, Robert S.
|
|
2005
|
23 |
17-18 |
p. 2057-2059
3 p.
|
article
|
| 75 |
Validation of the serum bactericidal assay for measurement of functional antibodies against group B meningococci associated with vaccine trials
|
Martin, D.
|
|
2005
|
23 |
17-18 |
p. 2218-2221
4 p.
|
article
|
Journal description